Netherlands ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

Netherlands Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The Netherlands Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $77 Mn in 2022 and is projected to reach $142 Mn in 2030, exhibiting a CAGR of 8% during the forecast period. In order to be better prepared for upcoming pandemics, the government of the Netherlands will place a greater emphasis on bolstering global health systems and international collaboration. Additionally, the effects of climate change on public health will receive additional attention. Additionally, the Netherlands will increase its spending on foreign health from $116.50 Mn in 2023 to $143.23 Mn in 2026. The %age of Dutch residents who have chosen the maximum eigen risico rate of $945.93 has increased from 25,7% in 2020 to 38,7% since the final insurance revealed their new rates for 2023, according to data from the price comparison website Independer.

Initially believed to only affect children, attention-deficit hyperactivity disorder (ADHD) is now recognized as a disorder that lasts into adulthood. A lot has been understood about ADHD in young or middle-aged individuals, but little is known about the condition in elderly people. Between 3% and 7% of school-aged children suffer from attention-deficit hyperactivity disorder, with an estimated prevalence of 4.4% for adults. The prevalence of ADHD among adults in The Netherlands between the ages of 18 and 75 is estimated to be between 1.5% and 2.5%, with no indication of a decline as people get older. In the Netherlands, mothers of children with ADHD experience indirect costs associated with job absenteeism and decreased productivity that is nearly three times higher than those of mothers of children without behavioral issues.

Both immediate-release and long-acting methylphenidate formulations are advised for the treatment. The choice of treatment is determined by the patient's and parents' preferences, the need for dose flexibility, and financial factors. Long-acting methylphenidate may be more appropriate for patients with adherence issues or for whom using medication may be discouraged due to the stigma associated with ADHD, such as those who are reluctant to take medication while attending school. In the Netherlands, teachers frequently administer medication. Patients who did not respond well to long-acting methylphenidate may benefit from switching to atomoxetine. A clinician may also choose to give atomoxetine based on patient or parent preferences for a non-stimulant drug or methylphenidate tolerance problems. Although acknowledged as a possible therapy for ADHD, long-acting forms of amphetamine (AMPH) are not yet approved for use in the Netherlands. There is a dearth of data to support this trend, but ADHD prevalence and the use of associated stimulant medications might have elevated in the Netherlands in recent years. In the Netherlands, the use of ADHD medications increased between 2001 and 2006, according to a recent analysis of prescription data, with the majority of first-time drug users receiving immediate-release methylphenidate prescriptions.

Market Dynamics

Market Growth Drivers

In the Netherlands, more people are being diagnosed with ADHD as a result of growing knowledge of the disorder, which has increased demand for ADHD treatment options like medication and therapy. Better diagnostic and therapeutic tools for ADHD are being developed. For instance, wearables and mobile apps can help track progress and monitor symptoms in real time, making it simpler to manage the condition. The Dutch government has put plans in place to enhance ADHD diagnosis and care. For instance, they are funding research into the condition and introducing guidelines for the diagnosis and treatment of ADHD thereby resulting in the growth of the Netherlands ADHD therapeutics market.

Market Restraints

Despite growing public knowledge of ADHD, there are still stigmas and false beliefs about the disorder. Underdiagnosis and inadequate care may result, which could slow the Netherlands ADHD therapeutics market's expansion. Some patients may not be able to receive treatment because of the high cost of ADHD treatments and medications. A smaller market and slower growth could result from this. The availability of generic medications may increase competition and result in lower costs as some ADHD medications approach the end of their patent life. This may restrict the market's expansion for branded ADHD medicines.

Competitive Landscape

Key Players

• Fagron (NLD)
• Europort Pharmaceuticals (NLD)
• Erasmus Pharma (NLD)
• Synerkine Pharma (NLD)
• Caldic (NLD)
• Neurovance
• Noven Pharmaceuticals
• Pfizer
• Shire
• Supernus Pharmaceuticals
• Tris Pharma

Healthcare Policies and Regulatory Landscape

The efficacy, safety, and quality of pharmaceutical goods for both humans and animals are evaluated and protected by the Medicines Evaluation Board (MEB). In the Netherlands, the MEB is the main provider of data on current pharmaceuticals, new uses, and current risk data. New drugs cannot be released by a pharmaceutical company onto the market until it has been examined and approved by the Medicines Evaluation Board. The process is known as business authorization. Holders of marketing authorizations are required by law to notify the authorization bodies of any negative events. Sponsors of drug clinical trials and organizations responsible for the trials must also adhere to detailed directions for the submission of reports. In some circumstances, a compassionate use program may allow doctors to administer medications without marketing authorization. This relates to a particular circumstance where the MEB believes that the availability of new medicines for a large number of patients (cohort) is crucial before the final marketing authorization is granted.